2026-11-10 - LD The Hague - CureVac Manufacturing v. Moderna - UPC-CFI-0001407/2026
- Aktenzeichen:
- UPC-CFI-0001407/2026
- Datum:
- Spruchkörper:
- Court of First Instance - The Hague (NL) Local Division
- Art:
- Order
- Parteien:
- CureVac Manufacturing GmbH v. Moderna, Inc., Moderna Netherlands B.V., Moderna Switzerland GmbH, Moderna Biotech Spain SL, ModernaTX, Inc., Moderna Poland Sp. z o.o. , Moderna Biotech UK Ltd, SAS Moderna France, Moderna Germany GmbH, Moderna Italy S.r.l., Moderna Norway AS, Moderna Sweden AB , Moderna Portugal Unipessoal LDA
Kernaussage: The judge-rapporteur of the The Hague Local Division confirmed a confidentiality regime the parties agreed after a case management hearing, superseding a provisional grant of Moderna's confidentiality application.
2026-11-10 - LD The Hague - CureVac Manufacturing
v.
Moderna
UPC-CFI-0001407/2026
routine
The judge-rapporteur of the The Hague Local Division confirmed a confidentiality regime the parties agreed after a case management hearing, superseding a provisional grant of Moderna's confidentiality application. The order sets up two tiers: information protected against third parties and the public under R. 262.2 RoP, and 'Manufacturing Process Information' whose access is also restricted on the claimant side under R. 262A RoP to its representatives, external experts on request, and one designated employee each of CureVac SE and BioNTech US, who must not be involved in mRNA manufacturing patent filings. The protected passages are excluded from R. 262.1(b) inspection, only a fully redacted Statement of Defence is available to third parties, the public is excluded from the oral hearing insofar as the information is discussed, and breaches may attract penalty payments. The Court also granted an agreed extension of the claimant's next deadline to 23 November 2026, with all later deadlines moving accordingly.